Exosomes is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Exosomes are small extracellular vesicles[@colombo2014] (EVs) ranging from 30 to 150 nm in diameter, released by virtually all cell types through the fusion of [@colombo2014]
multivesicular bodies (MVBs) with the plasma membrane. In the central nervous system, exosomes[@kalluri2020] are secreted by [neurons](/entities/neurons), [@raposo2013]
[astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia). [@emmanouilidou2010]
Exosome formation begins with the inward budding of the limiting membrane of late endosomes, producing intraluminal vesicles (ILVs) within multivesicular bodies (MVBs). Two principal pathways govern ILV formation: [@danzer2012]
ESCRT-Dependent Pathway. The Endosomal Sorting Complex Required for Transport (ESCRT) machinery consists of four complexes (ESCRT-0, -I, -II, -III) plus accessory proteins (ALIX, VPS4). ESCRT-0 recognizes ubiquitinated cargo on the endosomal membrane; ESCRT-I and -II induce membrane budding; and ESCRT-III mediates vesicle scission. ALIX bridges ESCRT-I and ESCRT-III and recruits specific cargo proteins. [@horie2024]
Exosomes is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Exosomes are small extracellular vesicles[@colombo2014] (EVs) ranging from 30 to 150 nm in diameter, released by virtually all cell types through the fusion of [@colombo2014]
multivesicular bodies (MVBs) with the plasma membrane. In the central nervous system, exosomes[@kalluri2020] are secreted by [neurons](/entities/neurons), [@raposo2013]
[astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia). [@emmanouilidou2010]
Exosome formation begins with the inward budding of the limiting membrane of late endosomes, producing intraluminal vesicles (ILVs) within multivesicular bodies (MVBs). Two principal pathways govern ILV formation: [@danzer2012]
ESCRT-Dependent Pathway. The Endosomal Sorting Complex Required for Transport (ESCRT) machinery consists of four complexes (ESCRT-0, -I, -II, -III) plus accessory proteins (ALIX, VPS4). ESCRT-0 recognizes ubiquitinated cargo on the endosomal membrane; ESCRT-I and -II induce membrane budding; and ESCRT-III mediates vesicle scission. ALIX bridges ESCRT-I and ESCRT-III and recruits specific cargo proteins. [@horie2024]
ESCRT-Independent Pathway. Ceramide-dependent budding occurs when neutral sphingomyelinase 2 (nSMase2) generates ceramide from sphingomyelin in the endosomal membrane. Ceramide's cone-shaped structure promotes spontaneous inward curvature. Tetraspanin-enriched microdomains (CD9, CD63, CD81) also facilitate ESCRT-independent ILV formation by clustering specific cargo. [@fiandaca2015]
Following ILV formation, MVBs either fuse with the plasma membrane (releasing ILVs as exosomes[@kalluri2020] into the extracellular space) or fuse with lysosomes for degradation. Rab GTPases (Rab27a, Rab27b, Rab11, Rab35) and SNARE proteins regulate the trafficking and membrane fusion events that determine exosome release ([Colombo et al., 2014](https://doi.org/10.1146/annurev-cellbio-101512-122326)). [@goetzl2016]
Exosomes carry a characteristic molecular cargo reflecting their endosomal origin: [@alvarezerviti2011]
| Component | Examples | Function | [@sun2025]
|---|---|---| [@bhatt2025]
| Tetraspanins | CD9, CD63, CD81 | Membrane organization; commonly used as exosome markers |
| [Heat shock proteins](/entities/heat-shock-proteins) | Hsp70, Hsp90 | Protein folding; antigen presentation |
| MVB biogenesis | ALIX, TSG101, VPS4 | ESCRT pathway components; exosome biogenesis markers |
| Membrane trafficking | Rab GTPases, annexins, flotillins | Vesicle transport and fusion |
| Nucleic acids | mRNA, miRNA, lncRNA, small RNA | Gene regulation in recipient cells |
| Lipids | Cholesterol, sphingomyelin, ceramide | Membrane rigidity; signaling |
| Disease-related cargo | [Aβ](/proteins/amyloid-beta-protein), [tau](/proteins/tau), [alpha-synuclein](/proteins/alpha-synuclein), [TDP-43](/proteins/tdp-43), PrP-Sc | Pathological protein spreading in neurodegeneration |
The lipid bilayer of exosomes[@kalluri2020] is enriched in cholesterol,
sphingomyelin, and glycosphingolipids relative to the parent cell membrane, conferring stability and resistance to degradation in biological fluids.
This composition enables exosomes[@kalluri2020] to survive transit
through blood, cerebrospinal fluid, and interstitial spaces ([Raposo & Stoorvogel, 2013](https://doi.org/10.1083/jcb.201211138)).
Each CNS cell type releases exosomes[@kalluri2020] with distinct cargo profiles and functional roles:
Neuronal exosomes[@kalluri2020] carry synaptic proteins (AMPA/[NMDA receptor](/entities/nmda-receptor)] receptor subunits, synaptotagmin), neurotrophic factors (BDNF, GDNF), and -- critically in
disease -- misfolded tau] and [amyloid-beta](/proteins/amyloid-beta). Neuronal exosomes[@kalluri2020] express surface markers L1CAM (L1 cell adhesion molecule) and NCAM (neural
cell adhesion molecule), which are exploited for immunocapture-based isolation from blood.
Astrocytic exosomes[@kalluri2020] transport glutamate transporters, complement proteins, and in neurodegeneration, can carry [APP](/entities/app-protein) fragments and inflammatory mediators. They express GLAST and [GFAP](/entities/glial-fibrillary-acidic-protein) as surface markers.
Microglial exosomes[@kalluri2020] are enriched in inflammatory cytokines (IL-1-beta, TNF-alpha), complement components, and activated caspases. [microglia](/cell-types/microglia)
In [Parkinson's Disease](/diseases/parkinsons-disease) and related synucleinopathies, [alpha-synuclein](/proteins/alpha-synuclein) oligomers and fibrils are packaged into exosomes[@kalluri2020] that function as "Trojan horses":
[TDP-43](/mechanisms/tdp-43-proteinopathy) Proteinopathy characterizes ~97% of ALS cases and ~45% of Frontotemporal Dementia (FTD) cases. Exosome-mediated TDP-43 propagation has been demonstrated through several lines of evidence:
[Microglia exosomes[@kalluri2020] are potent amplifiers of neuroinflammation in neurodegeneration:
The ability to isolate brain-derived exosomes[@kalluri2020] from peripheral blood offers a minimally invasive window into CNS pathology:
| Biomarker Strategy | Marker | Application |
|---|---|---|
| Neuronal exosome isolation | L1CAM+, NCAM+ immunocapture | Enriches brain-derived EVs from plasma |
| Exosomal Abeta42/40 | Reduced ratio in AD | Correlates with [amyloid PET](/entities/amyloid-pet) positivity |
| Exosomal p-tau181/217 | Elevated in AD | Tracks tau pathology; may predict conversion from MCI to dementia |
| Exosomal alpha-synuclein | Elevated in PD/DLB | Distinguishes synucleinopathies from tauopathies |
| Exosomal TDP-43 | Elevated in ALS/FTD-TDP | Differentiates TDP-43 from tau pathology in FTD |
| Exosomal [NfL](/proteins/nfl-protein)) | Elevated across neurodegeneration | General neurodegeneration marker |
| Exosomal synaptosomal proteins | Synaptotagmin, neurogranin, GAP-43 | Tracks synaptic loss |
Neuronal-derived exosomes[@kalluri2020] (NDEs) isolated from plasma using L1CAM antibodies show AD-related changes in [amyloid-beta](/proteins/amyloid-beta), phospho-tau, and insulin signaling proteins up to 10 years before clinical diagnosis. However, the specificity of L1CAM as a neuronal exosome marker has been debated, and newer approaches using NCAM, synaptophysin, or multi-marker panels are under development ([Fiandaca et al., 2015](https://doi.org/10.1016/j.jalz.2014.07.003); [Goetzl et al., 2016](https://doi.org/10.1096/fj.201500799)).
Exosomes possess intrinsic properties that make them attractive drug delivery vehicles for the CNS:
[BBB](/entities/blood-brain-barrier) Penetration. Exosomes naturally cross the [blood-brain barrier](/entities/blood-brain-barrier) through multiple mechanisms including receptor-mediated transcytosis (via integrins, tetraspanins, and transferrin receptors), macropinocytosis by brain endothelial cells, and interactions between exosomal integrin alpha-v-beta-3 and vascular adhesion molecules. This natural BBB-crossing capability eliminates the need for the complex engineering required by synthetic nanoparticles ([Sun et al., 2025](https://doi.org/10.1002/mco2.70386)).
Engineering Strategies. Exosomes can be modified to enhance targeting and therapeutic payload:
Recent advances continue to expand the understanding and therapeutic potential of exosomes[@kalluri2020] in neurodegeneration:
Interactive diagram showing EXOSOMES key relationships in the SciDEX knowledge graph (15 connections shown).
The study of Exosomes has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[DOI:10.1126/science.aau6977](https://doi.org/10.1126/science.aau6977)
[DOI:10.1146/annurev-cellbio-101512-122326](https://doi.org/10.1146/annurev-cellbio-101512-122326)
[DOI:10.1083/jcb.201211138](https://doi.org/10.1083/jcb.201211138)